Market closed

Cullinan Oncology/CGEM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cullinan Oncology

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Ticker

CGEM
Trading on

Industry

Biotechnology

Employees

85

CGEM Metrics

BasicAdvanced
$947M
Market cap
-
P/E ratio
-$3.10
EPS
-0.12
Beta
-
Dividend rate
$947M
-0.12
$30.19
$7.64
610K
28.872
28.22
0.231
0.417
-19.04%
-24.94%
1.44
1.44
-5.915
-6.13%
31.80%

What the Analysts think about CGEM

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Cullinan Oncology stock.

CGEM Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CGEM Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy CGEM

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cullinan Oncology stock?

Cullinan Oncology (CGEM) has a market cap of $947M as of October 06, 2024.

What is the P/E ratio for Cullinan Oncology stock?

The price to earnings (P/E) ratio for Cullinan Oncology (CGEM) stock is 0 as of October 06, 2024.

Does Cullinan Oncology stock pay dividends?

No, Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders as of October 06, 2024.

When is the next Cullinan Oncology dividend payment date?

Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders.

What is the beta indicator for Cullinan Oncology?

Cullinan Oncology (CGEM) has a beta rating of -0.12. This means that it has an inverse relation to market volatility.